17,274 Shares in ClearPoint Neuro, Inc. (NASDAQ:CLPT) Acquired by Balyasny Asset Management L.P.

Balyasny Asset Management L.P. acquired a new position in shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 17,274 shares of the company’s stock, valued at approximately $266,000. Balyasny Asset Management L.P. owned approximately 0.06% of ClearPoint Neuro at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. JPMorgan Chase & Co. increased its position in ClearPoint Neuro by 58.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 9,770 shares of the company’s stock worth $110,000 after purchasing an additional 3,612 shares in the last quarter. Conway Capital Management Inc. increased its position in ClearPoint Neuro by 13.9% in the 4th quarter. Conway Capital Management Inc. now owns 161,225 shares of the company’s stock valued at $2,480,000 after acquiring an additional 19,725 shares during the period. Barclays PLC increased its position in ClearPoint Neuro by 24.3% in the 3rd quarter. Barclays PLC now owns 5,674 shares of the company’s stock valued at $64,000 after acquiring an additional 1,109 shares during the period. Tower Research Capital LLC TRC acquired a new position in ClearPoint Neuro in the 4th quarter valued at approximately $93,000. Finally, Invesco Ltd. acquired a new position in ClearPoint Neuro in the 4th quarter valued at approximately $3,814,000. 30.08% of the stock is currently owned by institutional investors and hedge funds.

ClearPoint Neuro Stock Performance

NASDAQ:CLPT opened at $13.18 on Friday. The firm’s fifty day moving average is $12.87 and its 200-day moving average is $14.23. ClearPoint Neuro, Inc. has a 52 week low of $5.11 and a 52 week high of $19.22. The firm has a market cap of $368.90 million, a P/E ratio of -19.10 and a beta of 1.03.

ClearPoint Neuro (NASDAQ:CLPT) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.07). ClearPoint Neuro had a negative net margin of 59.64% and a negative return on equity of 62.10%. The firm had revenue of $8.49 million during the quarter, compared to the consensus estimate of $8.21 million. As a group, sell-side analysts anticipate that ClearPoint Neuro, Inc. will post -0.66 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. B. Riley upped their price target on shares of ClearPoint Neuro from $15.00 to $20.00 and gave the company a “buy” rating in a research report on Tuesday, January 28th. Stifel Nicolaus upped their price target on shares of ClearPoint Neuro from $19.00 to $25.00 and gave the company a “buy” rating in a research report on Tuesday, April 1st. Finally, Lake Street Capital upped their price target on shares of ClearPoint Neuro from $17.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday, January 21st.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.